|
1
|
Chan JF, To KK, Tse H, Jin DY and Yuen KY:
Interspecies transmission and emergence of novel viruses: Lessons
from bats and birds. Trends Microbiol. 21:544–555. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song
J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from
patients with Pneumonia in China. N Engl J Med. 382:727–733.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou
J, Liu W, Bi Y and Gao G: Epidemiology, genetic recombination, and
pathogenesis of coronaviruses. Trends Microbiol. 24:490–502.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhou P, Yang XL, Wang XG, Hu B, Zhang L,
Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al: A pneumonia outbreak
associated with a new coronavirus of probable bat origin. Nature.
579:270–273. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song
ZG, Hu Y, Tao ZW, Tian JH, Pei YY, et al: A new coronavirus
associated with human respiratory disease in China. Nature.
579:265–269. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kistler K, Huddleston J and Bedford T:
Rapid and parallel adaptive mutations in spike S1 drive clade
success in SARS-CoV-2. Cell Host Microbe. 30:545–555.e4.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Khan A, Khan T, Ali S, Aftab S, Wang Y,
Qiankun W, Khan M, Suleman M, Ali S, Heng W, et al: SARS-CoV-2 new
variants: Characteristic features and impact on the efficacy of
different vaccines. Biomed Pharmacother. 143(112176)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
World Health Organization (WHO): Tracking
SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
Accessed January 19, 2022.
|
|
9
|
Davies NG, Abbott S, Barnard RC, Jarvis
CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC,
Washburne AD, et al: Estimated transmissibility and impact of
SARS-CoV-2 lineage B.1.1.7 in England. Science.
372(eabg3055)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Centers for Disease Control and Prevention
(CDC): Science Brief: Emerging SARS-CoV-2 Variants. CDC, Atlanta,
GA, 2021. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html.
Updated January 2021.
|
|
11
|
Letko M, Marzi A and Munster V: Functional
assessment of cell entry and receptor usage for SARS-CoV-2 and
other lineage B betacoronaviruses. Nat Microbiol. 5:562–569.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hoffmann M, Kleine-Weber H and Pöhlmann S:
A Multibasic cleavage site in the spike protein of SARS-CoV-2 is
essential for infection of human lung cells. Mol Cell.
78:779–784.e5. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yang W and Shaman J: Development of a
model-inference system for estimating epidemiological
characteristics of SARS-CoV-2 variants of concern. Nat Commun.
12(5573)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Monel B, Planas D, Grzelak L, Smith N,
Robillard N, Staropoli I, Goncalves P, Porrot F, Guivel-Benhassine
F, Guinet ND, et al: Release of infectious virus and cytokines in
nasopharyngeal swabs from individuals infected with non-alpha or
alpha SARS-CoV-2 variants: An observational retrospective study.
EBioMedicine. 73(103637)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kidd M, Richter A, Best A, Cumley N, Mirza
J, Percival B, Mayhew M, Megram O, Ashford F, White T, et al:
S-variant SARS-CoV-2 lineage B1.1.7 is associated with
significantly higher viral loads in samples tested by TaqPath
Polymerase Chain Reaction. J Infect Dis. 223:1666–1670.
2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Calistri P, Amato L, Puglia I, Cito F, Di
Giuseppe A, Danzetta ML, Morelli D, Di Domenico M, Caporale M,
Scialabba S, et al: Infection sustained by lineage B.1.1.7 of
SARS-CoV-2 is characterised by longer persistence and higher viral
RNA loads in nasopharyngeal swabs. Int J Infect Dis. 105:753–755.
2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Walker AS, Vihta KD, Gethings O, Pritchard
E, Jones J, House T, Bell I, Bell JI, Newton JN, Farrar J, et al:
Tracking the emergence of SARSCoV-2 alpha variant in the United
Kingdom. N Engl J Med. 385:2582–2585. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shenai MB, Rahme R and Noorchashm H:
Equivalency of protection from natural immunity in COVID-19
recovered versus fully vaccinated persons: A systematic review and
pooled analysise. Cureus. 13(e19102)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vassallo M, Manni S, Klotz C, Fabre R,
Pini P, Blanchouin E, Sindt A, Lotte L, Dubertrand JM, Liguori S,
et al: Patients admitted for variant alpha COVID-19 have poorer
outcomes than those infected with the old strain. J Clin Med.
10(3550)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Turnbull CD, Porter BML, Evans SB, Smith
O, Lardner R, Hallifax R, Bettinson HV, Talbot NP, Bafadhel M,
Rahman NM, et al: Improved COVID-19 outcomes in a large
non-invasive respiratory support cohort despite emergence of the
alpha variant. BMJ open Respir Res. 8(e001044)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Elliott J, Whitaker M, Bodinier B, Eales
O, Riley S, Ward H, Cooke G, Darzi A, Chadeau-Hyam M and Elliott P:
Predictive symptoms for COVID-19 in the community: REACT-1 study of
over 1 million people. PLoS Med. 18(e1003777)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Weisblum Y, Schmidt F, Zhang F, DaSilva J,
Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH,
Michailidis E, et al: Escape from neutralizing antibodies by
SARS-CoV-2 spike protein variants. Elife. 9(e61312)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Resende P, Bezerra J, Teixeira Vasconcelos
RH, Arantes I, Appolinario L, Mendonça AC, Paixao AC, Duarte
Rodrigues AC, Silva T, Sampaio Rocha A, et al: Severe Acute
Respiratory Syndrome Coronavirus 2 P.2 Lineage Associated with
Reinfection Case, Brazil, June-October 2020. Emerg Infect Dis.
27:1789–1794. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang Z, Schmidt F, Weisblum Y, Muecksch F,
Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C,
Lieberman JA, et al: mRNA vaccine-elicited antibodies to SARS-CoV-2
and circulating variants. Nature. 592:616–622. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Moss DL and Rappaport J: SARS-CoV-2 beta
variant substitutions alter spike glycoprotein receptor binding
domain structure and stability. J Biol Chem.
297(101371)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jassat W, Mudara C, Ozougwu L, Tempia S,
Blumberg L, Davies MA, Pillay Y, Carter T, Morewane R, Wolmarans M,
et al: Difference in mortality among individuals admitted to
hospital with COVID-19 during the first and second waves in South
Africa: A cohort study. Lancet Glob Heal. 9:e1216–e1225.
2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Luna-Muschi A, Borges IC, de Faria E,
Barboza AS, Maia FL, Leme MD, Guedes AR, Mendes-Correa MC, Kallas
EG, Segurado AC, et al: Clinical features of COVID-19 by SARS-CoV-2
Gamma variant: A prospective cohort study of vaccinated and
unvaccinated healthcare workers. J Infect. 84:248–288.
2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Allen H, Vusirikala A, Flannagan J, Twohig
KA, Zaidi A, Chudasama D, Lamagni T, Groves N, Turner C, Rawlinson
C, et al: Household transmission of COVID-19 cases associated with
SARS-CoV-2 delta variant (B.1.617.2): National casecontrol study.
Lancet Reg Health Eur. 12(100252)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cherian S, Potdar V, Jadhav S, Yadav P,
Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S and Team N:
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the
Second Wave of COVID-19 in Maharashtra, India. Microorganisms.
9(1542)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Challen R, Dyson L, Overton CE,
Guzman-Rincon LM, Hill EM, Stage HB, Brooks-Pollock E, Pellis L,
Scarabel F, Pascall DJ, et al: Early epidemiological signatures of
novel SARS-CoV-2 variants: Establishment of B.1.617.2 in England.
medRxiv: doi: https://doi.org/10.1101/2021.06.05.21258365.
|
|
31
|
Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan
C, Shi J, Deng X, Jiang M, Zhong S, et al: Transmission, viral
kinetics and clinical characteristics of the emergent SARS-CoV-2
Delta VOC in Guangzhou, China. EClinicalMedicine.
40(101129)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ong SWX, Chiew CJ, Ang LW, Mak TM, Cui L,
Toh MPHS, Lim YD, Lee PH, Lee TH, Chia PY, et al: Clinical and
virological features of severe acute respiratory syndrome
coronavirus 2 (SARSCoV-2) variants of concern: A retrospective
cohort study comparing B.1.1.7 (Alpha), B.1.351 (Beta), and
B.1.617.2 (Delta). Clin Infect Dis: Aug 23, 2021 (Epub ahead of
print).
|
|
33
|
Twohig KA, Nyberg T, Zaidi A, Thelwall S,
Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R,
Lopez-Bernal J, et al: Hospital admission and emergency care
attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with
alpha (B.1.1.7) variants of concern: A cohort study. Lancet Infect
Dis. 22:35–42. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Loconsole D, Centrone F, Morcavallo C,
Campanella S, Accogli M, Sallustio A, Peccarisi D, Stufano A,
Lovreglio P and Chironna M: Changing Features of COVID-19:
Characteristics of Infections with the SARS-CoV-2 Delta (B.1.617.2)
and Alpha (B.1.1.7) Variants in Southern Italy. Vaccines (Basel).
9(1354)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ryu BH, Hong SI, Lim SJ, Cho Y, Hwang C,
Kang H, Kim SH, Wi YM, Hong KW, Bae IG and Cho OH: Clinical
Features of Adult COVID-19 Patients without Risk Factors before and
after the Nationwide SARS-CoV-2 B.1.617.2 (Delta)-variant Outbreak
in Korea: Experience from Gyeongsangnam-do. J Korean Med Sci.
36(e341)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Butt AA, Dargham SR, Chemaitelly H, Al
Khal A, Tang P, Hasan MR, Coyle PV, Thomas AG, Borham AM,
Concepcion EG, et al: Severity of Illness in Persons Infected With
the SARS-CoV-2 Delta Variant vs Beta Variant in Qatar. JAMA Intern
Med. 182:197–205. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chia PY, Ong SWX, Chiew CJ, Ang LW,
Chavatte JM, Mak TM, Cui L, Kalimuddin S, Chia WN, Tan CW, et al:
Virological and serological kinetics of SARS-CoV-2 Delta variant
vaccine breakthrough infections: A multicentre cohort study. Clin
Microbiol Infect. 28:612.e1–612.e7. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kim S, Nguyen TT, Taitt AS, Jhun H, Park
HY, Kim SH, Kim YG, Song EY, Lee Y, Yum H, et al: SARSCoV-2 omicron
mutation is faster than the chase: Multiple mutations on spike/ACE2
interaction residues. Immune Netw. 21(e38)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Meo SA, Meo AS, Al-Jassir FF and Klonoff
DC: Omicron SARS-CoV-2 new variant: Global prevalence and
biological and clinical characteristics. Eur Rev Med Pharmacol Sci.
25:8012–8018. 2021.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sofonea MT, Roquebert B, Foulongne V,
Verdurme L, Trombert-Paolantoni S, Roussel M, Haim-Boukobza S and
Alizonet S: From Delta to Omicron: Analysing the SARS-CoV-2
epidemic in France using variant-specific screening tests
(September 1 to December 18, 2021). medRxiv: doi: https://doi.org/10.1101/2021.12.31.21268583.
|
|
41
|
Abdullah F, Myers J, Basu D, Tintinger G,
Ueckermann V, Mathebula M, Ramlall R, Spoor S, de Villiers T, Van
der Walt Z, et al: Decreased severity of disease during the first
global omicron variant covid-19 outbreak in a large hospital in
tshwane, South Africa. Int J Infect Dis. 116:38–42. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Graham MS, Sudre CH, May A, Antonelli M,
Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, et
al: Changes in symptomatology, reinfection, and transmissibility
associated with the SARS-CoV-2 variant B.1.1.7: An ecological
study. Lancet Public Health. 6:e335–e345. 2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Wang S, Zou X, Li Z, Fu J, Fan H, Yu H,
Deng F, Huang H, Peng J, Zhao K, et al: Analysis of clinical
characteristics and virus strains variation of patients infected
with SARS-CoV-2 in Jiangsu Province-A retrospective study. Front
Public Health. 9(791600)2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Neagu M, Constantin C and Surcel M:
Testing antigens, antibodies, and immune cells in COVID-19 as a
public health topic-experience and outlines. Int J Environ Res
Public Health. 18(13173)2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lownik JC, Farrar JS, Way GW, McKay A,
Roychoudhury P, Greninger AL and Martin RK: Fast SARS-CoV-2 variant
detection using snapback primer high-resolution melting.
Diagnostics (Basel). 11(1788)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
de Puig H, Lee RA, Najjar D, Tan X,
Soekensen LR, Angenent-Mari NM, Donghia NM, Weckman NE, Ory A, Ng
CF, et al: Minimally instrumented SHERLOCK (miSHERLOCK) for
CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging
variants. Sci Adv. 7(eabh2944)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Lunca C, Cojocaru C, Gurzu IL, Petrariu FD
and Cojocaru E: Performance of antigenic detection of SARS-CoV-2 in
nasopharyngeal samples. medRxiv: doi: https://doi.org/10.1101/2021.07.12.21260263.
|
|
48
|
Buchta C, Camp JV, Jovanovic J, Radler U,
Benka B, Puchhammer-Stöckl E, Müller MM, Griesmacher A, Aberle SW
and Görzer I: Inadequate design of mutation detection panels
prevents interpretation of variants of concern: Results of an
external quality assessment for SARS-CoV-2 variant detection. Clin
Chem Lab Med. 60:291–298. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ruan Q, Yang K, Wang W, Jiang L and Song
J: Clinical predictors of mortality due to COVID-19 based on an
analysis of data of 150 patients from Wuhan, China. Intensive Care
Med. 46:846–848. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Ghebrehiwet B and Peerschke EI: Complement
and coagulation: Key triggers of COVID-19-induced multiorgan
pathology. J Clin Invest. 130:5674–5676. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Jacobs W, Lammens M, Kerckhofs A, Voets E,
Van San E, Van Coillie S, Peleman C, Mergeay M, Sirimsi S,
Matheeussen V, et al: Fatal lymphocytic cardiac damage in
coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis
signature. ESC Hear Fail. 7:3772–3781. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Timpani CA and Rybalka E: Calming the
(Cytokine) Storm: Dimethyl fumarate as a therapeutic candidate for
COVID-19. Pharmaceuticals (Basel). 14(15)2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wood H: New insights into the neurological
effects of COVID-19. Nat Rev Neurol. 16(403)2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cojocaru E, Cojocaru C, Antoniu SA, Stafie
CS, Rajnoveanu A and Rajnoveanu RM: Inhaled interferons beta and
SARS-COV2 infection: A preliminary therapeutic perspective. Expert
Rev Respir Med. 16:257–261. 2022.
|
|
55
|
US Food and Drug (FDA): FDA Approves First
COVID-19 Vaccine. FDA, Silver Spring, MD, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.
Accessed August 23, 2021.
|
|
56
|
Beigel JH, Tomashek KM, Dodd LE, Mehta AK,
Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et
al: Remdesivir for the treatment of Covid-19-Final Report. N Engl J
Med. 383:1813–1826. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Lavinio A, Ercole A, Battaglini D, Magnoni
S, Badenes R, Taccone FS, Helbok R, Thomas W, Pelosi P and Robba C:
collaborators. Safety profile of enhanced thromboprophylaxis
strategies for critically ill COVID-19 patients during the first
wave of the pandemic: Observational report from 28 European
intensive care units. Crit Care. 25(155)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Guy T, Créac'hcadec A, Ricordel C, Salé A,
Arnouat B, Bizec JL, Langelot M, Lineau C, Marquette D, Martin F,
et al: High-flow nasal oxygen: A safe, efficient treatment for
COVID-19 patients not in an ICU. Eur Respir J.
56(2001154)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Horwitz LI, Jones SA, Cerfolio RJ,
Francois F, Greco J, Rudy B and Petrilli CM: Trends in COVID-19
Risk-Adjusted Mortality Rates. J Hosp Med. 16:90–92.
2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Our World in Data: COVID-19 Data Explorer.
https://ourworldindata.org/explorers/coronavirus-data-explorer.
Accessed March 12, 2022.
|
|
61
|
Mercatelli D and Giorgi FM: Geographic and
genomic distribution of SARS-CoV-2 mutations. Front Microbiol.
11(1800)2020.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Shen Z, Xiao Y, Kang L, Ma W, Shi L, Zhang
L, Zhou Z, Yang J, Zhong J, Yang D, et al: Genomic diversity of
severe acute respiratory syndrome-coronavirus 2 in patients with
coronavirus disease 2019. Clin Infect Dis. 71:713–720.
2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Mlcochova P, Kemp SA, Dhar MS, Papa G,
Meng B, Ferreira IATM, Datir R, Collier DA, Albecka A, Singh S, et
al: SARS-CoV-2 B.1.617.2 Delta variant replication and immune
evasion. Nature. 599:114–119. 2021.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Long MJC and Aye Y: Science's Response to
CoVID-19. ChemMedChem. 16:2288–2314. 2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Muik A, Wallisch AK, Sänger B, Swanson KA,
Mühl J, Chen W, Cai H, Maurus D, Sarkar R, Türeci O, et al:
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by
BNT162b2 vaccine-elicited human sera. Science. 371:1152–1153.
2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Abdool Karim SS and de Oliveira T: New
SARS-CoV-2 variants-clinical, public health, and vaccine
implications. N Engl J Med. 384:1866–1868. 2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Pfizer: Pfizer and BioNTech Provide Update
on Omicron Variant. Pfizer, New York, NY 2021. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant.
Accessed December 08, 2021.
|
|
68
|
Cojocaru C, Cojocaru E, Radu S and Gurzu
B: Perception and attitude of the general population on the risk of
infection with SARS-CoV-2. J Biosci Med. 9:1–10. 2021.
|
|
69
|
Congressional Research Service: Global
Economic Effects of COVID-19, 2021. https://crsreports.congress.gov/. Updated November
10, 2021.
|
